Home

CARB-X is accelerating global antibacterial innovation by investing in the development of new antibiotics and other life-saving products to combat the most dangerous drug-resistant bacteria. Our projects represent the world’s largest pre-clinical and early development pipeline of antibiotics and other therapeutics, diagnostics, microbiome and vaccines. Since CARB-X was established in July 2016, it has invested $135 million in 47 projects in seven countries.

139+

$million

Invested

48

innovative

Projects

7

different

Countries

13

focused on new classes

Pipeline

The Challenge

Accelerate the development of novel antibiotics and other new approaches to address the emergence of drug-resistant superbugs.
Learn More


Spotlight on Science

SciBac is fighting fire with fire by using improved bugs as drugs

Learn More

“Antibiotics transformed modern medicine but overuse and inappropriate use have led to dangerous bacteria developing deadly resistance. Drug discovery must go hand-in-hand with concerted action to ensure antibiotics of last resort are reserved for patients where first-line treatments will not work. And we must ensure these treatments are available in all countries for those who need them.”

— Tim Jinks, Head of Drug Resistant Infections, Wellcome Trust
Watch this video with Tim Jinks on what Wellcome Trust is doing to address the rise of drug-resistant bacteria.

Funders

ASPR
BARDA
WellcomeTrust
NIAID
UK Government

Alliance Partners

Bill and Melinda Gates Foundation

Accelerators and other partners

Events

Events

09.23.19

New York City, NY

AMR Challenge: A Night Celebrating Global AMR Fighters

10.02.19

Washington D.C., DC

IDWeek 2019 Annual Conference

10.03.19

Boston, MA

Live Webinar: GARDP/REVIVE – Natural products antibiotics: from traditional screening to novel discovery approaches

CARB-X News

  • 09.17.2019  |  CARB-X funds Procarta Biosystems to develop oligonucleotide-based antibiotics to combat life-threatening Gram-negative pathogens full release

  • 09.11.2019  |  2018-19 Annual Report: Progress in CARB-X’s fight against drug-resistant bacteria with new funding, expertise and strategic focus full release

  • 09.03.2019  |  CARB-X Strengthens Leadership Team with Appointment of Erin Duffy as Chief of Research and Development (R&D) full release

See All News

In The News

  • 09.04.2019  |  Bugging Out – Drug-resistant pathogens, antibiotics … and the race against the clock full story

  • 08.28.2019  |  Biotechs fight fears of ‘antibiotic apocalypse’ full story

  • 08.15.2019  |  Vaccine against superbugs could be a game changer, say researchers full story

See All News

Sign up for CARB-X news

Get the latest news and announcements from CARB-X.